1. Home
  2. CBIO vs EFSI Comparison

CBIO vs EFSI Comparison

Compare CBIO & EFSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$13.13

Market Cap

252.6M

Sector

N/A

ML Signal

HOLD

Logo Eagle Financial Services Inc

EFSI

Eagle Financial Services Inc

HOLD

Current Price

$39.73

Market Cap

214.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
EFSI
Founded
2003
1881
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
252.6M
214.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CBIO
EFSI
Price
$13.13
$39.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$25.60
$39.50
AVG Volume (30 Days)
207.9K
13.6K
Earning Date
11-06-2025
10-23-2025
Dividend Yield
N/A
3.13%
EPS Growth
N/A
N/A
EPS
N/A
2.13
Revenue
N/A
$66,122,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$27.28
P/E Ratio
N/A
$18.59
Revenue Growth
N/A
3.18
52 Week Low
$9.81
$28.70
52 Week High
$21.40
$40.38

Technical Indicators

Market Signals
Indicator
CBIO
EFSI
Relative Strength Index (RSI) 45.86 71.86
Support Level $13.35 $39.51
Resistance Level $15.58 $40.38
Average True Range (ATR) 1.32 0.82
MACD -0.04 0.29
Stochastic Oscillator 17.28 77.29

Price Performance

Historical Comparison
CBIO
EFSI

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About EFSI Eagle Financial Services Inc

Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.

Share on Social Networks: